GSK Vaccine Could Cut Cervical Cancer by 80%
At Monday's International Society of Pharmacoeconomics and Outcomes Research 9th Annual European Congress (ISPOR) in Copenhagen, Denmark, Glaxosmithkline PLC (GSK) announced that based on a mathematical model typically used for estimating the effect of cancer vaccines in a population its own cervical cancer candidate could reduce the rate of this cancer in women by as much as 80%.
GSK's cancer vaccine has been developed to prevent infection with the most prevalent cancer causing sub-types of HPV, HPV16 and HPV18. This was shown in an earlier study where the company's vaccine prevented recurrent HPV infections in women between the ages of 15-25.
The company claims that over 16,000 women have been vaccinated with its cervical cancer vaccine. The vaccine is currently undergoing phase 3 clinical trials.
Shares of GSK closed on Friday at $53.28, down by about 3%.
_
At Monday's International Society of Pharmacoeconomics and Outcomes Research 9th Annual European Congress (ISPOR) in Copenhagen, Denmark, Glaxosmithkline PLC (GSK) announced that based on a mathematical model typically used for estimating the effect of cancer vaccines in a population its own cervical cancer candidate could reduce the rate of this cancer in women by as much as 80%.
GSK's cancer vaccine has been developed to prevent infection with the most prevalent cancer causing sub-types of HPV, HPV16 and HPV18. This was shown in an earlier study where the company's vaccine prevented recurrent HPV infections in women between the ages of 15-25.
The company claims that over 16,000 women have been vaccinated with its cervical cancer vaccine. The vaccine is currently undergoing phase 3 clinical trials.
Shares of GSK closed on Friday at $53.28, down by about 3%.
_
posted by Nico at
7:35 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home